Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (852 total)
-
Creator: Antar, Annukka A. R., Tong Yu, Nora Pisanic, Razvan Azamfirei, Jeffrey A. Tornheim, Diane M. Brown, Kate Kruczynski, Justin P. Hardick, Thelio Sewell, Minyoung Jang, Taylor Church, Samantha N. Walch, Carolyn Reuland, Vismaya S. Bachu, Kirsten…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-04-16
Description: Sustained molecular detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in the upper respiratory tract (URT) in mild to moderate coronavirus disease 2019 (COVID-19) is common. We sought to identify host and immune… -
Creator: Daniel, William, Marc Nivet, John Warner, and Daniel K. Podolsky.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-05-20
Description: Emergency use authorizations for two messenger RNA (mRNA) vaccines — the BNT162b2 vaccine (Pfizer–BioNTech) and the mRNA-1273 vaccine (Moderna) — marked important milestones in efforts to respond to the coronavirus disease 2019 (Covid-19) pandemic.…Example only: NETEC provides this item for reference purposes but does not endorse its content. Newer versions may be in place at the providing institution.
-
Creator: the ENSEMBLE Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-10
Description: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. -
Creator: Guetl, Katharina, Thomas Gary, Reinhard B. Raggam, Johannes Schmid, Albert Wölfler, and Marianne Brodmann.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-11
Description: A 50-year-old woman attended our emergency department with a 3-day history of severe back pain and a severe headache. 10 days earlier she had received the first dose of vaccine against SARS-CoV-2—ChAdOx1 nCoV-19 (AstraZeneca). The patient had no… -
Creator: Kamar, Nassim, Florence Abravanel, Olivier Marion, Chloé Couat, Jacques Izopet, and Arnaud Del Bello.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-06-23
Description: A weak immune response to two doses of vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in recipients of solid-organ transplants. -
Creator: Shantha, J. G., I. Crozier, C. S. Kraft, D. G. Grant, A. Goba, B. R. Hayek, C. Hartley, K. G. Barnes, T. M. Uyeki, J. Schieffelin, R. F. Garry, D. G. Bausch, P. E. Farmer, J. G. Mattia, M. J. Vandy, and S. Yeh.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-07-09
Description: Following the West African Ebola virus disease (EVD) outbreak of 2013-2016 and more recent EVD outbreaks in the Democratic Republic of Congo, thousands of EVD survivors are at-risk for sequelae including uveitis, which can lead to unremitting… -
Creator: Barda, Noam, Noa Dagan, Yatir Ben-Shlomo, Eldad Kepten, Jacob Waxman, Reut Ohana, Miguel A. Hernán, Marc Lipsitch, Isaac Kohane, Doron Netzer, Ben Y. Reis, and Ran D. Balicer.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-08-25
Description: Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the… -
Creator: Xia, ShengLi, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu…
Subject: Research
Item Type: Publication
Date Last Updated: 2021-09-15
Description: Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a key part in SARS-CoV-2 transmission. An efficacious vaccine for children and adolescents could therefore assist pandemic control.… -
Creator: Bar-On, Yinon M., Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, and Amit Huppert.
Subject: Research
Item Type: Publication
Date Last Updated: 2021-10-07
Description: On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5…